Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Cash & Equivalents: 2018-2021

  • Genmab A's Cash & Equivalents rose 65.01% to $1.1 billion in Q2 2021 from the same period last year, while for Jun 2021 it was $1.1 billion, marking a year-over-year increase of 65.01%. This contributed to the annual value of $843.4 million for FY2020, which is 128.32% up from last year.
  • Latest data reveals that Genmab A reported Cash & Equivalents of $1.1 billion as of Q2 2021, which was up 33.43% from $843.4 million recorded in Q4 2020.
  • Genmab A's 5-year Cash & Equivalents high stood at $1.1 billion for Q2 2021, and its period low was $61.76 during Q2 2019.
  • Moreover, its 3-year median value for Cash & Equivalents was $682.0 million (2020), whereas its average is $604.0 million.
  • Data for Genmab A's Cash & Equivalents shows a peak YoY spiked of 1,104,220,104.39% (in 2020) over the last 5 years.
  • Over the past 4 years, Genmab A's Cash & Equivalents (Quarterly) stood at $149.0 million in 2018, then surged by 147.85% to $369.4 million in 2019, then soared by 128.32% to $843.4 million in 2020, then surged by 65.01% to $1.1 billion in 2021.
  • Its last three reported values are $1.1 billion in Q2 2021, $843.4 million for Q4 2020, and $682.0 million during Q2 2020.